Table 6. Splenectomized Patients:... | American Society of Hematology

Table 6.

Splenectomized Patients: Treatment With High Doses of Anti-D

Patient No.	Dose (μg/kg)	Platelet Increase (×1,000/μL)	Hemoglobin Decrease (g/dL)
(A) IV administration of anti-D

1	90	4	0.7
2	110	3	0.4
3	130	−13	2.8
4	150	25	1.1
5	150	−5	1.7
	Median	3	1.1
6	200	17/52^6-150	0.6
7	200	3	0.4
8	200	59	0.4
9	200	13/30^6-150	0.5
10	200	7	2.2
11	200	135	1.6
	Median	15	0.55
(B) Subcutaneous administration of anti-D

6	80	3	+1.2
7	80	−11	+0.8
9	80	−10	0.5
10^6-151	80	3	0.1
11	80	34	0.3
	Median	3	+0.5

Patient No.	Dose (μg/kg)	Platelet Increase (×1,000/μL)	Hemoglobin Decrease (g/dL)
(A) IV administration of anti-D

1	90	4	0.7
2	110	3	0.4
3	130	−13	2.8
4	150	25	1.1
5	150	−5	1.7
	Median	3	1.1
6	200	17/52^6-150	0.6
7	200	3	0.4
8	200	59	0.4
9	200	13/30^6-150	0.5
10	200	7	2.2
11	200	135	1.6
	Median	15	0.55
(B) Subcutaneous administration of anti-D

6	80	3	+1.2
7	80	−11	+0.8
9	80	−10	0.5
10^6-151	80	3	0.1
11	80	34	0.3
	Median	3	+0.5

Platelet increase and hemoglobin decrease were evaluated 7 to 14 days after treatment. Median values for day 7 platelet and hemoglobin changes are shown.

F6-150

Two patients responded only on day 14.

F6-151

Patient no. 10 was also treated with 80 μg/kg Rhogam, an intramuscular form of anti-D, with no response.

View Large

This Feature Is Available To Subscribers Only